Published in AIDS Weekly, January 2nd, 2006
Through the HIV Vaccine Design and Development Teams (HVDDT) program, Wyeth will develop and clinically evaluate novel adjuvant-enhanced plasmid DNA (pDNA) and peptide based vaccines for use in a prime-boost therapeutic regimen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.